Esperion Announces the Appointment of Seth H.Z. Fischer to its Board of Directors
November 01 2021 - 7:00AM
Esperion (NASDAQ: ESPR) today announced the appointment of Seth
H.Z. Fischer as a Class III director, with a term expiring at the
2022 meeting of stockholders.
"On behalf of the Esperion team and our directors, I am very
pleased to welcome Seth to the Esperion board. His deep operational
and commercial expertise will be especially relevant during this
exciting and transformative time for our Company,” said Sheldon
Koenig, president and chief executive officer of Esperion. “Seth is
a proven leader with a successful track record of developing and
executing strategies to drive product growth, and we look forward
to leveraging his counsel to further our mission.
"I’m honored to join Esperion’s board of directors during this
transformational time ahead of the read-out of the unprecedented
CLEAR Outcomes trial," said Mr. Fischer. “The recent changes
Esperion implemented position the company for long-term success,
and I look forward to applying my previous experience to support
Esperion’s focused and driven team in ensuring the millions of
patients who need additional LDL-C lowering options have access to
our convenient, once-daily oral medicines.”
Mr. Fischer brings over 35 years of experience and a
distinguished record of results in key leadership positions within
the pharmaceutical and medical device industries. He currently
serves as a member of the board of directors of Agile Therapeutics,
Inc., Spectrum Pharmaceuticals, Inc., and Marinus Pharmaceuticals.
Previously, Mr. Fischer served as the chief executive officer and
as a director of Vivus, Inc., a publicly traded biopharmaceutical
company commercializing and developing innovative, next-generation
therapies to address unmet needs from September 2013 to December
2017.
Prior to Vivus, Mr. Fischer served in various positions of
increasing responsibility at Johnson & Johnson, most recently
as company group chairman, Johnson & Johnson and worldwide
franchise chairman of Cordis Corporation. Before that, he served as
company group chairman, North America Pharmaceuticals, which
included responsibilities for Ortho-McNeil Pharmaceuticals, Janssen
and Scios. Prior to that, Mr. Fischer served as president of
Ortho-McNeil Pharmaceuticals. From May 2013 to May 2019, Mr.
Fischer also served on the board of directors of BioSig
Technologies, Inc.
Mr. Fischer holds a Bachelor of General Studies from Ohio
University and previously served as a captain in the U.S. Air
Force.
Esperion TherapeuticsEsperion is The Lipid
Management Company. Our goal is lipid management for everybody,
that’s why we work hard to make our medicines easy to get, easy to
take and easy to have. We discover, develop and commercialize
innovative medicines and combinations to lower cholesterol,
especially for patients whose needs aren’t being met by the status
quo. Our entrepreneurial team of industry leaders is inclusive,
passionate and resourceful. We are singularly focused on managing
cholesterol so you can improve your health easily. For more
information, please visit www.esperion.com and follow us on Twitter
at www.twitter.com/EsperionInc.
Forward-Looking StatementsThis press release
contains forward-looking statements that are made pursuant to the
safe harbor provisions of the federal securities laws, including
statements regarding marketing strategy and commercialization
plans, restructuring and operational expenses, future operations,
commercial products, clinical development, plans for potential
future product candidates, financial condition and outlook, and
other statements containing the words “anticipate,” “believe,”
“estimate,” “expect,” “intend,” “may,” “plan,” “predict,”
“project,” “suggest,” “target,” “potential,” “will,” “would,”
“could,” “should,” “continue,” and similar expressions. Any express
or implied statements contained in this press release that are not
statements of historical fact may be deemed to be forward-looking
statements. Forward-looking statements involve risks and
uncertainties that could cause Esperion’s actual results to differ
significantly from those projected, including, without limitation,
the impact of the ongoing COVID-19 pandemic on our business,
revenues, results of operations and financial condition, the net
sales, profitability, and growth of Esperion’s commercial products,
clinical activities and results, supply chain, commercial
development and launch plans, and the risks detailed in Esperion’s
filings with the Securities and Exchange Commission. Any
forward-looking statements contained in this press release speak
only as of the date hereof, and Esperion disclaims any obligation
or undertaking to update or revise any forward-looking statements
contained in this press release, other than to the extent required
by law.
Contact:Esperion Media Relationscorporateteam@esperion.com
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From May 2024 to Jun 2024
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From Jun 2023 to Jun 2024